DPP-4抑制剂与炎症性肠病  

DPP-4 inhibitors and inflammatory bowel disease

作　　者：靳迺诗[1] 董志[1] 傅洁民[2] 曾凡新[2] 

机构地区：[1]重庆医科大学药学院药理教研室,重庆市400016 [2]重庆医药工业研究院,重庆市400061

出　　处：《世界华人消化杂志》2010年第30期3215-3219,共5页World Chinese Journal of Digestology

摘　　要：炎症性肠病(inflammatory bowel disease,IBD)是一种病因未明的慢性非特异性肠道炎症性疾病,包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn's disease,CD).DPP-4抑制剂是近年来发现的一种治疗糖尿病的新靶点药物,而最近有研究表明,DPP-4抑制剂对动物肠炎模型有一定的治疗作用,这可能为炎症性肠炎的治疗开辟新的治疗途径.Inflammatory bowel disease（IBD） is a chronic,debilitating disease associated with severe damage to the intestinal mucosa whose etiology is still unknown.The two most common forms of IBD are ulcerative colitis（UC） and Crohn＇s disease（CD） .DPP-4 inhibitors are a new class of agents developed for treatment of diabetes. However,recent studies have indicated that DPP-4 inhibitors have therapeutic effects against IBD in animal models.This may provide a new avenue to cure IBD.

关 键 词：二肽基肽酶-4抑制剂 炎症性肠病 胰高血糖素样肽-2 

分 类 号：R574[医药卫生—消化系统]